TNF and hidradenitis suppurativa: The use of tumor necrosis factor-alpha (TNF-alpha) inhibitors, namely adalimumab, has significantly advanced the management of hidradenitis suppurativa, but the optimal biomarkers to monitor systemic inflammation and therapeutic response remain debated to this day.